Cargando…

Dose Delays, Dose Reductions, and Relative Total Dose Intensity in Patients With Advanced Cancer Who Exercised During Neoadjuvant Chemotherapy Treatment

BACKGROUND: When it comes to chemotherapy, maintaining the dose and schedule of treatment are of vital importance, as clinical evidence suggests that dose intensity is associated with optimal treatment outcomes for various tumors. Yet, reduced dose intensity is a common method of mitigating the chem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wonders, Karen Y., Schmitz, Kathryn, Harness, Jay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126785/ https://www.ncbi.nlm.nih.gov/pubmed/37077136 http://dx.doi.org/10.1177/15347354231168368

Ejemplares similares

Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy
por: Martei, Yehoda M., et al.
Publicado: (2022)

Dose intensity in cancer chemotherapy.
por: Dodwell, D. J., et al.
Publicado: (1990)

High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer.
por: Ferguson, J. E., et al.
Publicado: (1993)

Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensity
por: Lancia, Carlo, et al.
Publicado: (2018)

Dose-Intense Cisplatin-Based Neoadjuvant Chemotherapy Increases Survival in Advanced Cervical Cancer: An Up-to-Date Meta-Analysis
por: Nguyen, Van Tai, et al.
Publicado: (2022)

Efficacy and safety of vinorelbine and cisplatin regimen of different doses and intensities for neoadjuvant chemotherapy in patients with locally advanced esophageal carcinoma
por: Jin, Ke, et al.
Publicado: (2021)

The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer
por: O’Neil, Daniel S, et al.
Publicado: (2023)

Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
por: Regan, Meredith M.
Publicado: (2022)

Management of chemotherapy dose intensity for metastatic colorectal cancer
por: Chu, Xuelei, et al.
Publicado: (2022)

Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
por: Ismail, R.K., et al.
Publicado: (2022)

Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC
por: Campedel, Luca, et al.
Publicado: (2020)

Cost-Savings Analysis of an Individualized Exercise Oncology Program in Early-Stage Breast Cancer Survivors: A Randomized Clinical Control Trial
por: Wonders, Karen Y., et al.
Publicado: (2022)

Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients
por: Liutkauskiene, Sigita, et al.
Publicado: (2015)

Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes
por: Liutkauskiene, Sigita, et al.
Publicado: (2018)

Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience
por: Bhatnagar, Bhavana, et al.
Publicado: (2014)

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
por: Canton, Clémence, et al.
Publicado: (2022)

Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma
por: Rožman, Samo, et al.
Publicado: (2022)

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
por: Liu, Stephanie N., et al.
Publicado: (2021)

Dose Reduction Techniques
por: Waggoner, L O
Publicado: (2000)

Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy
por: Karol, Seth E., et al.
Publicado: (2021)

The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity
por: Yabusaki, Norimitsu, et al.
Publicado: (2016)

Correction to: Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
Publicado: (2022)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Wang, Lize, et al.
Publicado: (2021)

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
por: Rodolico, Alessandro, et al.
Publicado: (2022)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Pneumocystis jirovecii Pneumonia in a Patient with Breast Cancer Receiving Neoadjuvant Dose-dense Chemotherapy
por: Watanabe, Hirofumi, et al.
Publicado: (2019)

Pneumocystis jirovecii Pneumonia in Three Patients With Breast Cancer Receiving Neoadjuvant Dose-Dense Chemotherapy
por: Shiiba, Ritsuya, et al.
Publicado: (2022)

Dose Reduction to the Scalp with Hippocampal Sparing Is Achievable with Intensity Modulated Radiotherapy
por: Witek, Matthew, et al.
Publicado: (2014)

Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer
por: PETTY, W. JEFFREY, et al.
Publicado: (2013)

How to calculate the dose of chemotherapy
por: Gurney, H
Publicado: (2002)

Electronic prescribing: Reducing delay to first dose of antibiotics for patients in intensive care
por: Matthews, Philippa C, et al.
Publicado: (2013)

Predictors of adherence to different types and doses of supervised exercise during breast cancer chemotherapy
por: Courneya, Kerry S, et al.
Publicado: (2014)

Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy
por: Chang, Hui, et al.
Publicado: (2020)

Optimal radiation dose in the neoadjuvant management of esophageal cancer
por: Buckstein, Michael
Publicado: (2020)

US won't delay second dose
por: Lawton, Graham
Publicado: (2021)

Patient-Related Characteristics Associated with Treatment Modifications and Suboptimal Relative Dose Intensity of Neoadjuvant Chemotherapy in Patients with Breast Cancer—A Retrospective Study
por: Kjeldsted, Eva, et al.
Publicado: (2023)

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Dose of dialysis in the intensive care unit: is the venom in the dose or in the clinical experience?
por: Lameire, Norbert, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_3tl1dgff844ohn1pijbkdqim2t